91
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Effects of Ecabet Sodium on Acute Mixed Reflux Esophagitis in Rats

, , , &
Pages 1408-1415 | Received 10 Jun 2009, Accepted 10 Sep 2009, Published online: 03 Nov 2009
 

Abstract

Objective. Ecabet sodium (ENa) is a drug that repairs epithelial cells in the digestive tract via selective adhesion to damaged tissue. While the principal cause of reflux esophagitis is gastroesophageal acid reflux, the involvement of duodenal juice has also been identified as an important factor. This study aimed to explore the effect of ENa in an acute mixed reflux esophagitis (AMRE) rat model. Material and methods. Eight-week-old male Wistar rats were used to prepare an AMRE model. There were four experimental groups: Group A (sham-operated rats), Group B (AMRE rats), Group C (AMRE rats dosed with ENa at 10 mg/kg), and Group D (AMRE rats dosed with ENa at 30 mg/kg). All rats were assessed for incidence of macroscopic esophageal lesions, esophagitis index, and pathological findings. Amylase activity, bile acid concentration in the digestive fluid retained in the esophagogastric lumen and ENa concentration in the esophageal mucosa were determined. Results. The incidence of esophagitis was 0% for Group A, 100% for Group B, 40% for Group C, and 20% for Group D. It was significantly lower for Groups C and D relative to Group B. The median esophagitis index was 0 for Group A, 58.2 for Group B, 0 for Group C, and 0 for Group D, and it was significantly lower for Groups C and D relative to Group B. The histological severity grade of esophagitis in Groups C and D was significantly less than that in Group B. Conclusion. Treatment with ENa inhibited the development of AMRE in rats.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.